α2-Adrenoceptor antagonists

IDrugs

Volumn 4, Issue 6, 2001, Pages 662-676

  Mayer, Patrice ^a   Imbert, Thierry ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2342667989     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (150)

1. Timmermans PB, Van Zwieten PA: a-Adrenoceptor agonists and antagonists. Drugs Future (1984) 9(1):41-55. McGrath JC, Brown CM, Wilson VG: Alpha-adrenoceptors: a critical review. Med Res Rev (1989) 9:408-533. Berlan M, Montastruc JL, Lafontan M: Pharmacological prospect for o,-adrenoeeptor antagonist therapy. Trends Pharmacol Sei (1992) 13:277-282. Timmermans PB, Chiu AT, Thoolen M: a-Adrenergic receptors. In: Comprehensive Medicinal Chemistry Volume 3. Emmett JC (Ed), Pergamon Press, London (1990):133-185.
2. Timmermans PB, van Zwieten PA: a, Adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chetn (1982)25:1389-1401. Hieble JP, Bondinell WE, Ruffolo Jr RR: a-and Adrenoceptors: From the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem (1995)38(18):3415-3444. MacDonald E, Kobilka BK, Scheinin M: Gene targeting - homing in on 0,-adrenoceptor-subtype function. 77PS (1997)18:211-219.
3. Timmermans PB, Kwa HY, Zwieten PA: Possible subdivision of postsynaptic a-adrenoceptors mediating presser responses in the pithed rat. Naunyn Schmiedeberg's Arch Pharmacol (1979) 310:189193. Willette RN, Hieble JP, Sauermelch CF: The role of alpha adrenoceptor subtypes in sympathetic control of the acralcutaneous microcirculation. J Pharmacol Exp Ther (1991) 256:599605.
4. Gingell JC, Lockyer R: Emerging pharmacological therapies for erectile dysfunction. Exp Opin Ther Pat (1999) 9:1689-1696. Cartledge J, Eardley I : Viagra and beyond. Curr Opin Cent Peripheral Nerv Syst Invest Drugs (1999) 1:240-247.
5. Cdca JR, Tanis SP: Recent advances in the discovery and development of potential antidiabetic agents. In: Annual Reports in Medicinal Chemistry. Bristol JA (Ed) Academic Press Inc, San Diego (1992)27:219-226.
6. Galitzky J, Lafontan M, Nordenström J, Amer P: Rote of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human tissue. J Clin Invest (1993) 91:1997-2003. Lafontan M, Berlan M: Fat cell ccj-adrenoceptors: The regulation of fat cell function and lipotysis. Endocrine Re v (1995)16(6):716-738. Berlan M, Lafontan M: The 0,-adrenergic receptor of human fat cells: comparative study of 0,-adrenergic radioligand binding and biological response. J Physiol (1982) 78:279-287.
7. Nutt DJ, Finder RM: 0,-Adrenoceptors and depression. J Psychopharmacol (1996) 3:35-42. Broekkamp CL, Leysen D, Peelers BW, Pinder RM: Prospects for improved antidepressants. J Med Chem (1995) 38(23):4615-4633. Dickinson SL: o,-Adrenoceptor antagonism and depression. Drug News Perspect 1991 4(4): 197-203. Leysen D, Pinder RM: Toward third generation antidepressants. In: Annual Reports in Medicinal Chemistry Bristol JA (Ed), Academic Press Inc, San Diego (1994) 29:1-12. Pinder RM, Wieringa JH: Thirdgeneration antidepressants. Med Res fie v (1993) 13(3):259-325.
8. Coull JT: 0,-Adrenoceptors in the treatment of dementia: an attentional mechanism? J Psychopharmacol (1996) 3:43-48.
9. This review points out the therapeutic potential of a,-adrenoceptor antagonists (in particular idazoxan and yohimbine) in the treatment of cognitive dysfunction.
10. Coupland NJ, Wilson SJ, Nutt DJ: -Adrenoceptors in panic and anxiety disorders. J Psychopharmacol ( 1996) 3:26-34.
11. Hertel P, Fagerquist MV, Svensson TH: Enhanced cortical dopamine output and antipsychotic-like effect of raclopride by a, adrenoceptor blockade. Science (1999) 286:105-107. Undström LH: Schizophrenia, the dopamine hypothesis and ct,-adrenoceptor antagonists. TiPS (2000) 21:198-199.
12. 77i/s study of the mode of the action of clozapine shows a potential of cortical dopamine output by use of an aadrenoceptor antagonist in combination with a dopamine agonist, and provides support lor the 'dopamine hypothesis of schizophrenia.
13. Myles JS: o,-Adrenoceptors in addiction. J Psychopharmacol (1996) 3:49-52.
14. Hieble JP, Ruffdo RR Jr. Subclassification and nomenclature of o,and 0,-adrenoceptors. Prog Drug Res (1996) 47:81-130. Hieble JP, Ruffolo Jr RR: Recent advances in the identification of a,- and
15. Link R, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, Barsh GS, Kobilka BK: Cardiovascular regulation in mice lacking o,adrenergic receptor subtype b and c. Science (1996) 273:803-805. MacMillan LB, Hein L, Smith MS, Piascik MT, Linbird LE: Central hypertensive effects of the cc adrenergic receptor subtype. Science (1996)273:801-803.
16. Both studies provide evidence for the putative functional rotes of a2adrenoceptor subtypes. ' '
17. Sallinen J, "Haapalinna T, Viitamaa T, Kobilka BK, Scheinin M: Adrenergic a-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci (1998) 18:3035-3042. Björklund M, Sirviö J, Puolivâli J, Sallinen J, Jäkäiä P, Scheinin M, Kobilka BK, Riekkinen P: o-adrenoceptoroverexpressing mice are impaired in executing nonspatial and spatial escape strategies. Mol Pharmacol (1998) 54:569-576. Sallinen J, Haapalinna A, MacDonald E, Viitamaa T, Lahdesmaki J, Rybnikova E, Pelto-Huiko M, Kobilka B, Scheinin M: Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry (1999) 4(5):443-452. Björklund M, Sirviö J, Riekkinen M, Sallinen J, Scheinin M, Riekkinen P: Overexpression of o-adrenoceptors impairs water maze navigation. Neuroscience (2000) 95(2):481-487.
18. Emerging evidence for the role of ax-adrenoceptors in the brain.
19. Colpaert F: Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neumpharmacology (1987) 26(9):1431-1440.
20. This study suggests for the first time the involvement of an a-adrenergic mechanism for alleviation of the reserpine-induced tremor and rigidity.
21. Henry B, Plowright A, Fox SH, Crossman AR, Brotchie JM: o,Adrenergic antagonists reduce symptoms in animal models of Ldopa-induced dyskinesia. Soc Neurosci Abstr (1997) 23(New Oreleans):Abs291.4.
22. Stone EA, Manavalan JS, Basham DA, Bing G: Effect of yohimbine on nerve growth factor mRNA and protein levels in rat hippocampus. Neurosci tett(1994) 167:11-13.
23. Montastruc JL, Berlan M: Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha-2adrenoceptor antagonist. Fundam Clin Pharmacol (1995) 9:248-254. Camacho F, Smith CP, Vargas HM, Winslow JT: 0,-Adrenoceptor antagonists potentiate acetylchoiinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology (1996) 124:347-354.
24. These studies highlight the role of a,-adrenoceptor antagonists in the activation of the cholinergic system.
25. Ernst E, Pittler MH: Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol (1998) 159:433-436. Toleken C, Rhoden EL, Sogari P, Dambros M, Souto CAV: Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol (1998) 159:122-124. Knoll LD, Benson RC, Bilhartz DL, Minich PJ, Furlow WL: A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol (1996) 155:144-146.
26. Sàenz de Tejada I, Garvey DS, Schroeder JD, Shelekhin T, Letts LG, Femandez A, Cuevas B, Gabancho S, Martinez V, Angulo J, Trocha M, Marek P, Cuevas P, Tarn SW: Design and evaluation of nitrosylated a-adrenergic receptor antagonists as potential agents for the treatment of impotence. J Pharmacol Exp Ther (1999) 290(1):121-128. Sàenz de Tejada I, Cuevas, P, Femandez A, Gabacho S, Letts LG, Schroeder JD, Shelekhin T, Tarn SW: Nitrosylated a-adrenergic receptor antagonists as potential drugs for the treatment of erectile dysfunction. J Urol (1997) 157(4 Suppl):Abs 791
27. Zheng W, Lei L, Lalchandani S, Sun G, Feller DR, Miller DD: Yohimbine dimers exhibiting binding setectiv'rties for human oversus 0,-adrenergic receptors. Bioorg Med Chem Lett (2000) 10:627-630.
28. Potent selectivity for human aa- versus a
29. Oberland C, Willig F, Dekeyne A, M'Harzi M, Sanderson P: Promnesic propertis of RU-52583 in relation with central noradrenergic activity in rodents: Can J Physiol Pharmacol (1994) 72(Suppl 1):361 Abs P13.7.8.
30. Clark R, Repke DB, Berger J, Nelson JT, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M: Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12, 12a,13,13a-decahydro-6/fisoquino[2,1-g][1,6]naphthyridines at cxadrenoceptors. J Med Chem (1991) 34:705-717. Clark R, Repke DB, Kilpatrick AT, Brown CM, MacKinnon AC, Clague RU, Spedding M: (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro3-metrK)xy-12meriylsulionyl)- 6>ffe[2,1-[1,6lnaphttiyridine, a potent and highly selective alpha 2-adrenoceptor antagonist. J Med Chem (1989) 32:2034-6. MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM: [!H]-RS-15385-197, a selective and high affinity radioligand for o,-adrenoceptors: implications for receptor classification. Br J Pharmacol (1992) 106:1011-1018. Brown CM, MacKinnon AC, Redfem WS, Hicks PE, Kilpatrick AT, Small C, Ramcharan M, Clague RU, Clark RD, MacFarlane CB, Spedding M: The pharmacology of RS-15385-197, a potent and selective o,adrenoceptor antagonist. Br J Pharmacol (1993) 108:516-525. Redfem WS, MacKinnon AC, Brown CM, Martin AB, Kilpatrick AT, Clague RU, Spedding M: Modulation of central noradrenergic function by RS-15385-197. Br J Pharmacol (W93) 108:526-533.
31. Rhodes KF, Waterfall JF: The effects of some a-adrenoceptor antagonists on the response of the canine saphenous vein to B-HT 933, UK-14304 and methoxamine. Naunyn Schmiedeberg's Arch Pharmacol (1987) 335:261-268.
32. Munoz M, Bancroft J, Turner M : Evaluation of the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 1. The erectile response to erotic stimuli in volunteers. Psychopharmacology (1994) 115:463-470. Munoz M, Bancroft J, Turner M: Evaluation of the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers. Psychopharmacology (1994)115:471-477.
33. Enas JD, Clark RD, VanBrocklin HF, Budinger TF: Synthesis and biological evaluation of fluorine-18 labeled RS-15385-197 analogs: potent and selective alpha-2 adrenergic receptor radioligands for PET. /CS(1997) 213(San Fransisco):MEDI 171.
34. Yamamoto O, Niida H, Tajirha K, Shirouchi Y, Kyotani Y, Ueda F, Kise M, Kimura K: Effect of YNS-15P, a new a, adrenoceptor antagonist, on stress stimulated colonie propulsion in rats. J Pharmacol Exp Ther(1998) 287(2):691-696.
35. Uhlèn S, Porter AC, Neubig RR: The novel alpha-2 adrenergic radioligand ['HJ-MK912 is alpha-2C selective among human alpha2A, alpha-SB and alpha-2C adrenoceptors. J Pharmacol Exp Ther (1994)271:1558-1565.
36. Clineschmidt BV. Pettibone DJ, Lotti VJ, Hucker HB, Sweeney BM, Reiss DR, Lis EV, Huff JR, Vacca J: A peripherally acting alpha-2 adrenoceptor antagonist: L-659066. J Pharmacol Exp Ther (1988) 245(1 ):32-40. Sciberras DG, Reed JW, Elliott C, Blain PG, Goldberg MR: The effects of a peripherally selective ct,-adrenoceptor antagonist, MK-467, on the metabolic and cardiovascular response to exercise in healthy man. Br J Clin Pharmacol (1994) 37:39-44.
37. Zelle RE, Hancock AA, Buckner SA, Basha FZ, Tietje K, DeBemardis JF, Meyer MD: Synthesis and pharmacological characterization of ABT-200: a putative novel antidepressant combining potent a-2 antagonism with moderate NE uptake inhibition. Bioorg Med Chem Le(1994)4(11):1319-1322.
38. Meyer DM, Hancock AA, Tietje K, Sippy KB , Giardina WJ, Kerwin Jr JF: Synthesis and pharmacological characterization of A-80426: a putative novel antidepressant combining a-2 antagonism with 5-HT uptake inhibition. Bioorg Med Chem Lett (1995) 5(19):2287-2292. Meyer DM, Hancock AA, Tietje K, Sippy KB, Prasad R, Stout DM, Arendsen DL, Donner BG, Carroll WA: Structure-activity studies for a novel series of NarylethyI)-W-(1,2,3,4-tetrahydronaphtalen-1ylmethyl}-W-methylamines possessing dual 5-HT. uptake inhibiting and ct,-antagonistic activities. J Med Chem (1997) 40(7): 1049-1062.
39. Giardina WJ, Buckner SA, Brune ME, Hancock AE, Wismer CT, Milicic l, Rattin AJ, Roux S, Wettstein JG, Meyer MD, Porsort RD, Kerwin JF, Williams M: A-80426, a potent and selective o,-adrenoceptor antagonist With serotonin uptake blocking activity and putative antidepressant effects: II. Pharmacology profile. Drug Dev Res (1995) 35:246-260. Srameck JJ, Jasinsky O, Chang S, Shu V, Kashkin K, Kennedy S, Sadd C, Cutler NR: Pilot efficacy of ABT-200 in patients with major depressive disorders. Depression (1995) 2:315318.
40. Stambach JF, Kanmacher l, Jung L, Schott C, Heitz C, Stodet JC: 2AminobenzyM,2,3,4-tetrahydroisoquinolines: a new class of ct,adrenergic receptor antagonists. Eur J Med Chem (1993) 28:427432.
41. Treatment of extrapyramidal movement disorders. Drug Data Rep (2000) 22(8):684. ' '
42. Kennis LEJ, Bischoff FP, Mertens CJ, Love CJ, Van den Keybus FAF, Pieters S, Braeken M, Megens AA, Leysen JE: New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central
43. Bioorg Med Chem Lett (2000) 10:71 -74.
44. Mottram DR, Kapur H: The adrenoceptor blocking effects of a new benzodioxane. J Pharm Pharmacol (1975) 27:295.
45. Colpaert FC, Raeymaekers L: In vivo pharmacological activity of R47243 in rat: a comparison with putative 0,-adrenoceptor antagonists. Drug Dev Res (1986) 8:361-371.
46. Colpaert FC, Degryse AD, van Cranendonck H: Effect of an a, antagonist in a 20-year-old Java Monkey with MPTP-induced parkinsonian signs. Brain Res u//(1991) 26:627-631. The first in vivo evidence concerning the role of an aadrenoceptor antagonist for the treatment of the MPTP-lnduced parkinsonian symptoms.
47. Mayer P, Brunei P, Chaplain C, Calmel F, Piedecoq C, Marien M, Chopin P, Pauwels P, Vidaluc JL, Imbert T: New benzodioxanemethyl-piperidine derivatives acting on ot,-adrenoceptors. Nat Med Chem Symp (1998) 26(Richmond):Abs D1. Mayer P, Brunei P, Chaplain C, Calmel F, Piedecoq C, Marien M, Schambel P, Chopin P, Wurch T, Pauwels P, Vidaluc JL, Imbert T: New substituted 1-(2,3dihydrobenzo[1,4]dioxin-2-ylmethyI)-piDeridin-4-yl derivatives with
48. Mayer P, Brunei P, Chaplain C, Calmel F, Piedecoq C, Pauwels P, Chopin P, Marien M, Vidaluc JL, Imbert T: Modulation of the benzodioxane heterocycte in a novel series of potent o,adrenoceptor antagonists. ACS (1999) 217(Anaheim):MED1112.
49. Imbert T, Mayer P, Brunei P, Piedecoq C, Schambel P, Vidaluc JL, Chopin P Pauwels P, Marien M: Conformation-activity relationship in a series of bertzodioxanemethyl tropane derivatives acting at ct,adrenoceptors. ACS (2000)219(San Francisco):MED1114.
50. Oa, Antagonist Investigational Drugs Weekly Highlights (1999) 6 Jan: 17.
51. Màtyus P: GYKI-16084. Drugs Future (1999) 24(10):1072-1077.
52. Halliday CA. Jones BJ, Skingle M, Walsh DM, Wise H, Tyers MB: The pharmacology of fluparoxan: a selective o,-adrenoceptor antagonist Br JP/7armaco/(1991) 102:887-895.
53. Dickinson SL: Alpha-2 adrenoceptor antagonism and depression.
54. Drugs News Perspect (1991 ) 4:197-203.
55. Procopiou PA, Cherry PC, Deal MJ, Lamont RB: A reinvestigation of the synthesis of trans-(±)-1|2,3,4,4a,10a-hexahydro[1,4]benzodixono[2,3-c]pyridine. J Chem Soc Perkin Trans 1 (1994): 1773-1777. Kitchin J, Borthwick AD, Brodie AC, Cherry PC, Crame AJ, Pipe AJ, Procopiou PA, Seaman MA, Tumbull JP: Synthesis of benzodioxinopyrroles as selective o,-adrenoceptor antagonists. Bioorg Med Chem (1995) 3(12): 1595-1603. Procopiou PA, Brodie AC, Deal MJ, Hayman DF, Smith GM: Novel cyclodehydration reaction of hydroxyphenols. An alternative to the M'rtsunobu reaction. J Chem Soc Perkin Trans 1 (1996):2249-2256.
56. Mayer P, Brunei P, Pauwels P, Marien M, Imbert T: Synthesis and biological evaluation of some ' new compounds acting on o,adrenergic receptors. Int Symp Med Chem Neurodegen Dis (1997) 3 (Key Biscayne):Poster 9.
57. Pinder RM: Antidepressants: Thirty years on. Leonard BE, Spencer PSJ (Eds), CNS Clinical Neuroscience, London (1990):335-348.
58. Murphy DL, Mitchell PB, Potter WZ: Novel pharmacological approaches to the treatment of depression. In : Psychopharmacology, the fourth generation of progress. Bloom FE, Kupfer DJ (Eds), Raven Press, New York (1995):1143-1153. De Boer T: Th effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharm (1995) 10(Suppl 4):19-23. Nutt D: Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand (1997) 96(Suppl 391):31-37. De Boer T, Nefkens F, Van Helvoirt A, Van Delft AMI: Differences in modulation of noradrenergic and serotonergic transmission by alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J PharmacolExp 77ier(1996) 277:852-860.
59. Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A: Mianserin, a 5-HT and a, antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol (1997) 20(3):210-214.
60. Pact V, Giduz T: Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology (1999) 53:1154. Wunsch H: Could the antidepressant mirtazapine be used to treat tremor? The Lancet (1999)354:1100.
61. The authors observed reduction or elimination of parkinsonian tremor and levodopa-induced tremor in five patients treated with the 0,-adrenoceptor antagonist mirtazapine.
62. Aarsland D, Larsen JP, Um NG, Wermouth L, Been P: Alpha-2adrenoceptor antagonism and serotonin reuptake inhibition in patients with Parkinson's diseases and depression. EUT
63. Neuropsychopharmacol (1999) 9(Suppl 5):S329 Abs P.4.030.
64. Young P, Berge J, Chapman H, Cawthome MA: Novel o,adrenoceptor antagonists show selectivity for o- and oadrenoceptor subtypes. Eur J Pharmacol (1989) 168:331-386.
65. Reports on highly selective compounds for a, over a.
66. Qureshi A: Vasomax Zonagen. Curr Opin Cent Peripheral Nerv Syst Invest Drugs (1999) 1 (2):262-267. Graul A, Castaner J: Phentolamine mesylate. Drugs Future (1998) 23(7):725-728.
67. PDA imposes cSnfcalhoH on Zonagen's Vasomax. Scrip (1999) 2463:17.
68. Hong S-S, Lee H, Miller DD: Synthesis and biological evaluation of bioisosteric analogues of phentolamine. Med Chem Res (1997) 7(1):53-65.
69. Ghika J, Tennis M, Hoffman EBA, Schoenfeld D, Grodon J: Idazoxan treatment in progressive supranuctear palsy. Neurology (1991) 41:986-991.
70. Evidence for the clinical effect of idazoxan in a neurodegenerative disease.
71. Coull JT, Sahakian BJ, Hodges JR: The (-antagonist idazoxan remediates certain attentional and executive dysfunction in patients w'rth dementia of frontal type. Psychopharmacology (1996) 123:239-249.
72. Evidence for the activity of idazoxan in short-term memory.
73. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM: The 0,-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances arrtiparkinsonian action of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord (1999) 14(5):744-753. Bezard E, Brefel C, Tison F, Peyro-SaJnt-Paul H, Ladure P, Rased O, Gross CE: Effect of the a, adrenoceptor antagonist, idazoxan, on motor disabilities in MPTPtreated monkey. Prog Neuro Psychopharmacol Biol Psychiatry (1999) 23:1237-1246. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ: Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedeberg's Arch Pharmacol (2000)361:181-186.
74. Studies comparing the motor effects of idazoxan to that of L-dopa in MPTPlesioned monkeys provide support for the usefulness of ct,-adrenoceptor antagonists in the treatment of Parkinson's disease.
75. Potter WZ: Idazoxan and response to typical neuroteptics in treatmentresistant schizophrenia. BrJ Psychiatry (1996) 168:571-579.
76. Smith A, Sturgess W, Rich N, Brice C, Collison C, Bailey J, Wilson S, Nutt D: The effect of idazoxan on reaction times, eye movements and the mood of healthy volunteers and patients with upper respiratory tract illness. J Psychopharmacol ( 1999) 13(2): 148-151.,
77. Thalamas C, Galitzky J, Senard JM, Lafontan M, Montastruc JL, Berfan M, Barbe P : Glucose-induced 'sympathetic activity and energy expenditure during acute 0,-adrenergic antagonism in obese subjects. Int J Obesity (2000) 24:695-700.
78. Sailings MR, Chapleo CB, Butler RCM, Davis JA, England CD, Myers PL, Tweddle N, Welboum AP, Doxey JC, Smith CFG: ct-Adrenoceptor reagents. 3. Synthesis of some 2-substHuted 1,4-benzodioxans as selective presynaptic 0,-adrenoceptor antagonists. J Med Chem (1985)28:1054-62.
79. Chapleo CB, Myers PL, Butler RCM, Davis JA, Doxey JC, Higgins SD, Myers M, Roach AG, Smith CFC, Stillings MR, Welboum AP: aAdrenoceptor reagents. 2. Effect of modification of the 1,4benzodioxan ring system on a-adrenoceptor activity. J Med Chem (1984)27:570-576.
80. Hume SP, Lammertsama AA, Opacka-Juffry J, Ahier RG, Myers R, Cremer JE, Hudson AL, Nuu DJ, Pike VW: Quantification of in vivo binding of ['H]RX 821002 in rat brain: evaluation as a radioligand for central c-adrenoceptors. Nuc/Med B/o/(1992) 19(8):841-849.
81. Tellez S, Colpaert F, Marien M: 0,-Adrenoceptor modulation of cortical acetylcholine release In vivo. Neuroscience (1999) 89(4):1041-1050. Martel JC, Chopin P, Colpaert F, Marien M: Neuroprotective effect of the 0,-adrenoceptor antagonists, (+)efaroxan and (±)-idazoxan, against quinolinic acid-induced lesions of the rat striât um. Exp Neural (1998) 154:595-601.
82. Results of these studies suggest a therapeutic potential of a2-adrenoceptor antagonists in neurodegenerative impairments, particularly Alzheimer's disease.
83. Mayer P, Brunei P, Imbert T: A new efficient synthesis of efaroxan. Bioorg Med Chem Lett (1999) 9:3021-3022. Couture K, Gouverneur V, Mioskowski C: A new approach to the synthesis of efaroxan. Bioorg Med Chem Lett (1999) 9:3023-3026.
84. Angel I, Grosset A, Perrault G, Schoemaker H, Langer SZ: In vivo pharmacological profile of SL-840418, a new selective peripherally active 0,-adrenoceptor antagonist Eur J Pharmacol (1993) 234:137145.
85. Beeley U, Berge JM, Chapman H, Hieble P, Kelly J, Naselky DP, Rockell CM, Young PW: Synthesis of a selective c-adrenoceptor antagonist, BRL-48962, and its characterization at cloned human uadrenoceptors. Bioorg Med Chem (1995) 3(12):1693-1698.
86. Synthesis of a selective a-adrenoceptor antagonist.
87. Perrone MH, Hamel LT, Ferrari RA, Haubrich DR: Napamezole, an alpha-2 adrenergic receptor antagonist and monoamine uptake inhibitor in vitro. J Pharmacol Exp 7r?er(1990) 254(2):471-475.
88. Cordi A, Berque-Bestel I, Persigand T, Lacoste JM, Newman-Tancredi A, Gobert A, Brocco M, Rivet JM, Millan MJ: Search for novel antidepressants through synergy between a, adrenoceptor antagonism and monoamine uptake inhibition. Int Symp Med Chem (2000) 16(Bdogna):PB57.
89. Caroon JM, Clark RD, Kluge AF, Olah R, Repke DB, Unger SH, Michel AD, Whiting RL: Structure-activity relationships for 2-substituted imidazoles as a,-adrenoceptor antagonists. J Med Chem (1982) 25:666-670.
90. Michel AD, Loury DN, Whiting RL: Assessment of imiloxan as a selective ot-adrenoceptor antagonist. Br J Pharmacol (1990) 99:560-564.
91. Cordi AA, Snyers MP, Giraud-Mangin D, Van der Maesen C, Van Hoeck JP, Beuze S, Ellens E, Napora F, Gillet CL, Gorissen H, Calderon P, Remade MD, Janssens de Varebeke P, Van Dorsser W, Roba J: Synthesis and structure-activity of 4<5)-<2,2-diphenylethyl) imidazoles as new 0,-adrenoceptor antagonists. Eur J Med Chem (1990)25:557-568.
92. Bagley JR, Brockunier LL, Kudzma LV, Pandit CR, Pratt DV, Galdes A, Jerussi TP, Del Vecchio RA: Synthesis and
93. Clarke KW, England GCW: Medetomidine, a new sedative-analgesic for use in the dog and its reversal with atipamezole. J Small Animal Pract (1989) 30:343-348.
94. . Lammintausta R, Finnegan K, Uyeno E, Csemansky JG: Behavioral effects of atipamezole, a selective 0,-antagonist, in rats.
95. Psychopharmaco/ogy (1988) 96(Suppl):Abs 31.02.28.
96. Kartiuvaara S, KaJIo A, Scheinin M, Anttila M, Salonen JS, Scheinin H: Pharmacological effects and pharmacokinetics of atipamezole, a novel 0,-adrenoceptor antagonist - a randomized, double-blind cross-over study in healthy male volunteers. Br J Clin Pharmacol (1990)30:97-106.
97. Viitamaa T, Haapalinna A, Heinonen E: The effect of the o,adrenoceptor antagonist, atipamezole, on the sexual behaviour of sexually low-active male rats. Behav Pharmacol (1995) 6(5-6):634635.
98. Santti E, Raasmaja A, Rouai J, Koulu M, Pesonen U, Huupponen R: The effects of atipamezole and MVP-1743 III, two 0,-adrenoceptor antagonists, on brown adipose tissue thermogenesis in obese Zucker rats. Int J Obesity (1396) 20(Suppl 4):Abs 08-184-WP1.
99. Haapalinna A, Sirviô J, Lammintausta R: Facilitation of cogn'rtive functions by a specific o,-adrenoceptor antagonist, atipamezole.
100. Ear J Pharmacol (1998) 347:29-40. Haapalinna A, Sirviô J, MacDonald E, Virtanen R, Heinonen E: The effects of a specific o,-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. Eur J Pharmacol (2000) 387:141-150.
101. The results presented are relevant for the potential use of 0,-adrenoceptor antagonists for the treatment for Alzheimer's disease and palliative treatment for demented Parkinsonian patients.
102. Haapalinna A, Virtanen S, Heinonen E: Atipamezole enhances the effects of levodopa and apomorphine in a rodent Parkinson model. Mov Disord (1996) 11(Suppl 1):Abs P550. Leino T, Haapalinna A, Heinonen E: Alpha 2-adrenoceptor antagonists potentiate antiparkinsonian effects of levodopa and apomorphine and reduce dopaminergic adverse effects. Soc Neurosci (1997) 23(New Oi1eans):Abs 165.18.
103. These results highlight the potential treatment of Parkinson's disease with atipamezole.
104. Heinonen P, Sipilä H, Neuvonen K, Lonnberg H, Cockcroft VB, Wurster S, Virtanen R, Savota MKT, Salonen JS, Savda JM: Synthesis and pharmacological properties of 4(5)-{2-ethyl-2,3-dihydro-2-silainden2-yl)imidazole, a silicon analogue of atipamezole. Eur J Med Chem
105. Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R : Anti-obesity effect of MPV-1743 III, a novel imidazoline derivative, in genetic obesity. Eur J Pharmacol
106. Hieble JP, DeMarinis RD, Fowler PJ, Matthews WD: Selective alpha-2 adrenoceptor blockade by SK&F-86466: in vitro characterization of receptor selectivity. J Pharmacol Exp 7/ier(1986) 236:90-96.
107. Hieble JP, Rutfolo RR: Subclassification and nomenclature of a,and 0,-adrenoceptors. In: Progress In Drug Research. E Jucker (Ed) BirkhauserVelag, Basel (1996)47:81-130.
108. George P, Borg F, O'Connor S, Lechaire J, Arbilla S, Pimoule C, Graham D, Wedzikowsky T, Langer SZ: Uroselective a,-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur
109. J Med Chem (1995) 30(Suppl):299s-310s.
110. Corsano S, Strappaghetti G, Barbara R, Giannaccini G, Betti L, Lucacchini A: Synthesis of new pyridazinone derivatives and their affinity towards 0,-0,-adrenoceptors. Bioorg Med Chem (1999) 7:933941.
111. Silvestre J, Graul A, Castaner J: Suneprtron hydrochloride. Drugs Future (1998) 23(2):161-165.
112. Millan MJ, Gobert A, Newmann-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL: SI 8327 (1-{2-[4-{6-fluoro-1,2-benzisoxazol-3yl)piperid-1-yl]ethyl)3-phenyl-imida2olin- 2-one), a'novel, potential antipsychotic displaying marked antagonist properties at a,- and ctradrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther (2000) 292:38-53.
113. Munk SA, Arasasingham P, Manlapaz C, Kharlamb A, Padillo E, Runde E, Hasson D, Wijono M, Lai R, Burke J, Wheeler L, Garst M: Synthesis and evaluation of conformationalty restrained amino oxazolines äs 0,-adrenergic agents. ACS (1997) 213 (San Fransisco):MEDI 29.
114. Nicholls IA, Morrison SF, Brinkworth Rl, Alewood PF, Andrews PR: Central nervous system receptor binding profiles of some 2-amino4-phenyl quinolines: a novel class of o,-adrenoceptor selective ligand. Life Sc/(1996) 53:343-347.
115. Szmuszkovicz J, VonVoigtlander PF, Kane MP: A new nontricyclic antidepressant agent Synthesis and activity of W-[trans-2(dimethylamino)cyclopentyl}-W-(3,4-dichlorophenyl)propanamide and related compounds. J Med Chem (1981)24:1230-1236.
116. Honkanen A, Ingman K, Korpi ER, Savola JM: JP-1730, a novel o,adrenoceptor antagonist enhances apomorphine- and L-dopainduced circling behavior in the rat. Soc Neuroscience -4bs(r(1999) 25(Miami Beach):Abs 541.19. Savola JM, Merivuori H, Engström M, Wurster S, Honkanen A: JP-1730, a novel antagonist of alpha-2adrenoceptors, has potential as new treatment for Parkinson's disease. Mov Disord (2000) 15(Suppl 3):24 Abs P.247. These studies with JP-1730 support and reinforce the role of or,adrenoceptor antagonists forthe treatment of Parkinson's disease.
117. Murrin LC, Gerety ME, Happe K, Bylund DB: Inverse agonism at o,adrenoceptors in native tissue. EUT J Pharmacol (2000) 398:185-191. Pauwels PJ, tardif S, Wurch T, Colpaert F: Facilitation of constitutive Ou-adrenoceptor activity by both single amino acid mutation (Thr'"Lys) and G protein coexpression: evidence for inverse agonism. J Pharmacol Exp Ther (2000) 292:654-663.
118. Classification of some a-adrenoceplor antagonists following their inverse agonism properties in native tissue and in recombinant human ctadrenoceptors.
119. Pauwels PJ, Colpaert FC: Heterogeneous ligand-mediated Ca" responses at wt and mutant o-adrenoceptors suggest multiple ligand activation binding sites at o-adrenoceptor. Neuropharmacology (2000) 39:2101-2111. Pauwels PJ, Colpaert FC: Disparate ligand-mediated Ça" responses by wild-type, mutant Ser Ala and SerAla o-adrenoceptor: G0l, fusion proteins: evidence for multiple ligand-activation binding sites. Br J Pharmacol (2000) 130:1505-1512. Molderings GJ, Menzel S, Kathrnann M, Schlicker E, Göthert M: Dual interaction of agmatine with the rat o-adrenoceptor: competitive antagonism and allosteric activation. BrJ Pharmacol (2000) 130:1706-1712.
120. Data suggesting that multiple activation binding sites exist for ctuadrenoceptor.
121. NEW YORK UNIVERSITY (Stone EA, Bing G): Method of using alpha 2antagonists for the treatment of neurodegenerative diseases. US05281607-A (1994). SAVOLA JUHA-MATTI (Haapalinna A, Viitamaa T, Sallinen J, Scheinin M, Savola JM): A method for the treatment of mental illness in mammals and a composition therefor. WO09851310 (1998).
122. HEALTH & PHARMA MARKETING Co LTD (Gomy P): Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunction. WO-09940917 (1999).
123. REAL 2000 LTD (Gomy P): Medicine containing yohimbine and arginine for treating erectile dysfunction. WO-U9901132 (1999).
124. NITROMED INC (Garvey DS, Schroeder JD, Saenz De Tejada I): NKrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses. WO-09727749 (1997).
125. ROUSSEL UCWF SA (Clémence F, Haesslein JL, Oberländer C): 20,21Dinorebumam'me derivatives, substituted in position 15, process for their preparation and novel intermediates so obtained, their use as medicines and compositions containing them. EP-00424248 (1991).
126. ROUSSEL-UCLAF SA (Becourt P, Dubois JL, Metziger P): Pharmaceutical compositions containing dinorebumamenine derivatives. EP-00729749 (1996)." '
127. MERCK AND Co INC (Pendelton RG : Us of 0,-adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonie spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions. EP-
128. NIPPON SHINYAKU Co LTD (Yamamoto O, Shiouchi Y): Benzoquinolizine derivatives and medicinal compositions. WO-09740046 (1997).
129. GJ, Merriman MC, Palermo MG): Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds. US-05192789 (1993).
130. ABBOTT LABORATORIES (DeBemardis JF, Zelle RE, Basha Z): 1Aminomethyl-1,2,3,4-tetrahydronaphthalenes. US-05128362 (1992). ABBOTT LABORATORIES (Meyer Ml, DeBemardis JF, Prasad R, Sippy KB, Tietje KR): Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors. WO-09312754 (1993).
131. ABBOTT LABORATORIES (Debemardis JF, Arendsen DL, Zelle RE): Aminomethyl-chroman compounds. US-05089519 (1992). ABBOTT LABORATORIES (Debemardis JF, Arendsen DL, Zelle RE): Aminomethylthiochroman compounds. US-05140039 (1992).
132. ABBOTT LABORATORIES (DeBemardis JF, Zelle RE): 6-Substftuted1,2,3,4-tetrahydroisoquinolines. US-04963563 (1990).
133. JANSSEN PHARMACEUTICA NV (Kenne LEJ, Love CH, Bischoff FP): 1Ä3.4Tetrahydro-benzofuro[3,2-c]pvridine derivatives. WO-O9845297 (1998).
134. JANSSEN PHARMACEUTICA NV (Kennis LEJ, Mertens JC, Braeken M): Tricyclic A3-piperidines as pharmaceuticals. WO-00020423 (2000).
135. PIERRE-FABRE MEDICAMENT (Vidaluc JL, Imbert T, Marien M, Briley M): Novel piperidine derivatives 4-substituted by an imidazolidinon-1yl-ethyl and 1,3-diazepinon-1-yl-ethyl group, and use thereof as o,adrenergic receptor antagonists. WO-09728157 (1997).
136. PIERRE-FABRE MEDICAMENT (Vidaluc JL, Imbert T, Marien M, Briley U): Novel benzodioxanes and 1-(2H)-benzopryranes, their preparation and their use as medicine. WO-09802435 (1998).
137. HOKURIKU SEIYAKU Co LTD (Kato H, Iwasaki N, Ikeda Y, Azuma T): Cyclic amine derivatives. JP-11180979 (1999).
138. PIERRE-FABRE MEDICAMENT (Mayer P, Imbert T, Marien M): Nouveaux
139. GYOGYSZERKUTATO INTEZET KFT (Matyus P, Harsing L, Karim M, Kosary J, Papp A, Simay A, Tilahun Y, Tomori E, Horvath E, Horvath K, Varga I, Zara E, Bidlo M, Druga A, Rabloczky G, Varga M, Karpati E, Kasztreiner E, Kiraly I, Mathe I, Mathe G, Sebestyen L, Makk N): 3(2H)-pyridazinone derivatives and pharmaceutical compositions containing these compounds. WO-09638441 (1996).
140. ZONAGEN INC (Podolski JS): Combination therapy for modulating the human sexual response. WO-09852569 (1998).
141. PIERRE FABRE MEDICAMENT (Mayer P, Imbert T, Couture K, Gouverneur V, Mioskowski C): Procédé de préparation de dérives 2,3dihydrobenzofurane-2,2-disubstmjés. FR-02780967 (2000).
142. SYNTHéLABO (Bedoya Z M, Diaz MJA, Del Sol MG, Martin EPU, Jimenez BMD, Romanach FM): 5,6-Dihydro-4H feno[3,4-c]pyrrole derivatives, their preparation and their therapeutic use. EP-00682028 (1995).
143. ADIR & Co (Cordi A, Lacoste JM, Millan M, Newman-Tancredi A, Gobert A): Imidazoline derivatives, preparation and pharmaceutical compositions containing them. EP-01010693 (2000).
144. FARMOS YHTYMA OY (Karjalainen AJ, Virtanen RE, Kaijalainen AL, Kurkela KOA): 4-Dihydroinden-2-yl, 4-tetrahydronaphty-2-yl, and 4dihydrobenzofuran-2-ylimidazotes, useful to block a,-adrenergic receptors. US-04689339 (1987).
145. ORION CORP (Pertovaara A, Linnankoski I, Virtanen R): Use of atipamezole for the treatment of male sexual impotence. WO-
146. ORION CORP (Karjalainen AJ, Virtanen RE, Kaijalainen AL, Parhi SSL, Eloranta MM, Haapalinna AS): Enantiomers of 4-{5-fluoro-2,3dihydro-1H-inden-2-yi)-1H-imidazole. WO-09500492 (1995).
147. SYNTHéLABO (Bedoya ZM, Diaz MJA, Del Sol G, Maartin EU, Jimenez BMD, Romanach FM, Purcell TA, Jegham S, Defosse G): Dérivés de 2,3-dihydro-1H-indole, leur préparation et leur application en thérapeutique. FR-02735776 (1996).
148. SMITHKLINE BEECHAM CORPORATION (Bondinell WE, Demarinis RM, Ku TW, Pfeiffer FR, Shah DH, Venslavsky JW): Furo- and thieno[4,3,2e/][3]benzazepines useful as alpha adrenergic receptor antagonists. US-05599310 (1997).
149. ALLERGAN INC (Munk SA, Garst ME, Burke JA): Conformationally rigid bicyclic and adamantane derivatives useful as alpha 2adrenergic blocking agents. WO-09601813 (1996).
150. STERLING WINTHROP INC (Mattes KC, Venepalli BR): Antiarrhythmic agents. US-05183813 (1993).